Auditory and electroencephalographic effects of midazolam and α-hydroxy-midazolam in healthy subjects

British Journal of Clinical Pharmacology

Volumn 49, Issue 1, 2000, Pages 72-79

  Hotz, Michel A ^a   Ritz, Rudolf ^b   Linder, Lilly ^c   Scollo Lavizzari, Giuseppe ^d   Haefeli, Walter E ^e  

^a UNIVERSITY OF BERN   (Switzerland)

^b Division of Intensive Care   (Sweden)

^c Division of Clinical Pharmacology   (Sweden)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acoustically evoked potentials; Electroencephalogram; Healthy volunteers; Midazolam; Pharmacokinetics; Transiently evoked otoacoustic emissions; hydroxy midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; BENZODIAZEPINE DERIVATIVE; DRUG METABOLITE; MIDAZOLAM;

ADULT; ARTICLE; AUDITORY NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COCHLEA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ELECTROENCEPHALOGRAM; EVOKED OTOACOUSTIC EMISSION; EVOKED RESPONSE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION;

EID: 0033966015     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00104.x     Document Type: Article

References (36)

1. 1 Breimer LTM, Hennis PJ, Burm AGL, et al. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling. Clin Pharmacokinet 1990; 18: 245-253.
2. 2 Loughnan BL, Sebel PS, Thomas D, Rutherfoord CF, Rogers H. Evoked potentials following diazepam or fentanyl. Anaesthesia 1987; 42; 195-198.
3. 3 Thürauf N, Ditterich W, Kobal G. Different sensitivity of pain-related chemosensory potentials evoked by stimulation with CO2 tooth pulp event-related potentials and acoustic event-related potentials to the tranquilizer diazepam. Br J Clin Pharmacol 1994; 38: 545-555.
4. 4 Milligan KR, Lumsden J, Howard RC, Howe JP, Dundee JW. Use of auditory evoked responses as a measure of recovery from benzodiazepine sedation. J Royal Soc Med 1989; 82: 595-597.
5. 5 Lehnhardt E. Praxis der Audiometrie. 7 Auflage, Stuttgart-New York: Thieme, 1997: 251-313.
6. 6 Probst R, Lonsbury-Martin BL, Martin GK. A review of otoacoustic emissions. J Acoust Soc Am 1991; 89: 2027-2067.
7. 7 Moller AR, Janetta PJ. Neural generators of the auditory brainstem response. In The Auditory Brainstem Response, ed Jacobson JT. London. Taylor & Francis Ltd, 1985: 13-31.
8. 8 Cody DTR, Jacobson JI Walker JL, Bickford RG. Averaged evoked myogenic and cortical potentials to sound in man. Ann Otol Rhinol Laryngol 1964; 73: 763-777.
9. 9 Gibson WPR. Essentials of clinical electric response audiometry. Edinburgh, London New York. Churchill Livingstone, 1978: 132-156.
10. 10 Stöhr M, Dichgans J, Diener HC, Buetner UW. Evozìerte Potentiale. Berlin, Heidelberg New York. Springer Verlag, 1982: 371-376.
11. 11 Ziegler WH, Shalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 1983; 16: 63S-69S.
12. 12 Ha HR, Rentsch KM, Kneer J, Vonderschmitt DJ. Determination of midazolam and its α-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit 1993; 15: 338-343.
13. 13 Gibaldi M, Perrier D. Pharmacokinetics. Vol 15 2nd edn. New York. Dekker, 1982: 199-219, 319-353, 445-449.
14. 14 Hotz MA, Allum JHJ, Kaufmann G, Follath F, Pfaltz CR. Shifts in auditory brainstem reponse latencies following plasma level controlled aminoglycoside therapy. Eur Arch Otorhinolaryngol 1990; 247: 202-205.
15. 15 Mendel MI. Influence of stimulus level and sleep stage on the early components of the averaged electroencephalic response to clicks during all night sleep. J Speech Res 1974; 17: 5-17.
16. 16 Kemp DT. Stimulated acoustic emissionsfrom within the human auditory system. J Acoust Soc Am 1978; 64: 1386-1391.
17. 17 Persson MP, Nilsson A, Hartvig P. Relation of sedation and amnesia to plasma concentrations of midazolam in surgical patients. Clin Phamacol Ther 1988; 43: 324-331.
18. 18 Michalk S, Moncorge C, Fichelle A, et al. Midazolam infusion for basal sedation in intensive care: absence of accumulation. Intens Care Med 1988; 15: 37-41.
19. 19 Bell GD, Antrobus JHL, Lee J, Coady T, Morden A. Bolus or slow titrated injection of midazolam prior to upper gastrointestinal endoscopy? Relative effect on oxygen saturation and prophylactic value of supplemental oxygen. Aliment Phamacol Ther 1990; 4: 393-401.
20. 20 Bell GD, Reeve PA, Moshiri M, et al. Intravenous midazolam: a study of the degree of oxygen desaturation occurring during upper gastrointestinal endoscopy. Br J Clin Pharmacol 1987; 23: 703-708.
21. 21 Bornemann LD, Min BH, Crews T, et al. Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 1985; 29: 91-95.
22. 22 Heizmann P, Eckert M, Ziegler WH, Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983; 16: 43S-49S.
23. 23 Vree TB, Baars AM, Booij LHD, Driessen JJ. Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high-performance liquid chromatography. Arzneimittelforschung/Drug Res 1981; 31: 2215-2219.
24. 24 Mandema J, Tuk B, van Stenveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-728.
25. 25 Jones JG, Konieczko E. Hearing and memory in anaesthetised patients. Br Med J 1986; 292: 1291-1293.
26. 26 Kochs E. Schulte am Esch J. Neurophysiologisches Monitoring und Benzodiazepinwirkung. Anästh Intensivther Notfallmed 1988; 23: 145-152.
27. 27 Schulte am Esch J, Koch SE. Midazolam and flumazenil in neuroanaesthesia. Acta Anaesthesiol Scand 1990; 34: 96-102.
28. 28 Plinkert PK, Möhler H, Zenner HP. A subpopulation of outer hair cells possessing GABA receptors with tonotopic organization. Arch Otorhinolaryngol 1989; 246: 417-422.
29. 29 Picton TW, Hillyard SA, Krausz HI, Galambos R. Human evoked potentials. I. Evaluation of components. Electroenceph Clin Neurophysiol 1974; 36: 179-190.
30. 30 Schwender D, Klasing S, Madler C, Poppel E, Peter K. Effects of benzodiazepines on midlatency auditory evoked potentials. Can J Anaesth 1993; 40: 1148-1154.
31. 31 Mendel MI, Goldstein R. Early component of the averaged electro-encephalic response to constant clicks during all-night sleep. J Speech Res 1971; 14: 829-840.
32. 32 Graham JM, Hurron JNF, Beagley HA. Postauricular myogenic response during traces tympanic electrocochleotrophy. Br J Audiol 1975; 9: 116-127.
33. 33 Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives; ethanol. In The Pharmacological Basis of Therapeutics. Ninth Edition, eds. Hardman JG, Goodman Gilman A, Limbird LE. New York: MacGraw-Hill, 1996: 365-366.
34. 34 Malizia AL, Gunn RN, Wilson SJ, et al. Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. Neuropharmacol 1996; 35: 1483-1491.
35. 35 Douek EE, Ashcroft PB, Humphries KN. The clinical value of the postauricular myogenic crossed acoustic responses in neuro-otology. In Disorders of Auditory Function, II, ed. Stephens SDG. London: Academic Press, 1976: 139-143.
36. 36 Clifford-Jones RE, Clarke GP, Mayles P. Crossed acoustic response combined with visual and somatosensory evoked responses in the diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 1979; 42: 749-752.